SAT0374 Lesinurad (LESU) adjunctive therapy with allopurinol (ALLO) in patients not responding to allo monotherapy: pooled post hoc safety and efficacy analysis in a patient subgroup using concomitant diuretics at baseline (BL)

Abstract

BackgroundLESU is approved as adjunctive therapy in combination with xanthine oxidase inhibitors (XOI) for gout PT not responding to XOI alone1. Gout PT often have hypertension (HT) for which diuretics...